Inventor · disambiguated record
Yue-Sheng Li
Also filed as: LI YUE-SHENG · LI YUE-SHENG LUKE
34 granted patents·14 pending applications·667 citations·filing 1990–2025
98Inventor score
Top patents by PatentIndex Score
48 records- 0198US8642546B2FGF21 mutant fusion polypeptides and uses thereofBELOUSKI EDWARD JOHN·Filed 2011·Granted Feb 4, 2014·64 cites·11 claims
- 0298US8410051B2FGF21 mutants and uses thereofBELOUSKI EDWARD JOHN·Filed 2011·Granted Apr 2, 2013·63 cites·21 claims
- 0398US8361963B2Uses of FGF21 polypeptides comprising two or more mutationsAMGEN INC·Filed 2011·Granted Jan 29, 2013·64 cites·4 claims
- 0498US8034770B2FGF21 polypeptides comprising two or more mutationsAMGEN INC·Filed 2009·Granted Oct 11, 2011·63 cites·15 claims
- 0597US8835385B2FGF21 polypeptides comprising two or more mutations and uses thereofBELOUSKI EDWARD JOHN·Filed 2012·Granted Sep 16, 2014·48 cites·26 claims
- 0697US8795985B2FGF 21 polypeptides comprising two or more mutations and uses thereofBELOUSKI EDWARD JOHN·Filed 2012·Granted Aug 5, 2014·48 cites·18 claims
- 0797US8618053B2FGF21 mutants multimers and uses thereofBELOUSKI EDWARD JOHN·Filed 2012·Granted Dec 31, 2013·45 cites·18 claims
- 0897US8188040B2FGF21 mutants and uses thereofBELOUSKI EDWARD JOHN·Filed 2010·Granted May 29, 2012·59 cites·21 claims
- 0996US8410043B2Stabilized activin IIB receptor polypeptides and uses thereofSUN JEONGHOON·Filed 2009·Granted Apr 2, 2013·54 cites·15 claims
- 1094US9273114B2Stabilized receptor polypeptides and uses thereofAMGEN·Filed 2013·Granted Mar 1, 2016·19 cites·31 claims
- 1194US9273106B2FGF mutants with reduced proteolysis and aggregationAMGEN INC·Filed 2013·Granted Mar 1, 2016·9 cites·21 claims
- 1294US7790859B2Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitorsAMGEN INC·Filed 2007·Granted Sep 7, 2010·24 cites·29 claims
- 1393US11072640B2Methods of treating non-alcoholic steatohepatitis using FGF21 mutantsAMGEN INC·Filed 2018·Granted Jul 27, 2021·3 cites·12 claims
- 1493US10308704B2Isolated nucleic acid molecules encoding stabilized receptor polypeptides and uses thereofAMGEN INC·Filed 2016·Granted Jun 4, 2019·12 cites·8 claims
- 1593US10011642B2Methods of treating of diabetes and obesity using FGF21 mutantsAMGEN INC·Filed 2016·Granted Jul 3, 2018·4 cites·28 claims
- 1693US7335743B2Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitorsAMGEN INC·Filed 2003·Granted Feb 26, 2008·45 cites·17 claims
- 1792US12152060B2Interleukin-2 variants and methods of uses thereofCUGENE INC·Filed 2023·Granted Nov 26, 2024·1 cites·6 claims
- 1891US2025136653A1FGF21 Mutants and Uses ThereofAMGEN INC·Filed 2024·Application pending·0 cites
- 1990US2024076333A1FGF21 Mutants and Uses ThereofAMGEN INC·Filed 2023·Application pending·0 cites
- 2088US11634467B2Cytokine-based bioactivatable drugs and methods of uses thereofCUGENE INC·Filed 2019·Granted Apr 25, 2023·3 cites·9 claims
- 2188US9493530B2FGF21 mutants comprising a mutation at position 98, 171 and/or 180AMGEN INC·Filed 2014·Granted Nov 15, 2016·10 cites·25 claims
- 2287US9562108B2Carrier immunoglobulinsAMGEN INC·Filed 2014·Granted Feb 7, 2017·8 cites·24 claims
- 2384US2023295267A1Stabilized receptor polypeptides and uses thereofAMGEN INC·Filed 2023·Application pending·0 cites
- 2482US8734796B2Carrier immunoglobulinsWALKER KENNETH W·Filed 2010·Granted May 27, 2014·5 cites·22 claims
- 2581US8906371B2Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitorsAMGEN INC·Filed 2013·Granted Dec 9, 2014·3 cites·31 claims
- 2681US8529893B2Methods for treating IFN-γ mediated diseases using human anti-IFN-γ neutralizing antibodies as selective IFN-gamma pathway inhibitorsWELCHER ANDREW A·Filed 2012·Granted Sep 10, 2013·4 cites·20 claims
- 2780US12319723B2Cytokine-based bioactivatable drugs and methods of uses thereofCUGENE INC·Filed 2023·Granted Jun 3, 2025·0 cites·9 claims
- 2880US11840558B2Methods of treating non-alcoholic steatohepatitis using FGF21 mutantsAMGEN INC·Filed 2021·Granted Dec 12, 2023·0 cites·23 claims
- 2980US9279013B2FGF-21 mutants comprising polyethylene glycol and uses thereofWALKER KENNETH W·Filed 2009·Granted Mar 8, 2016·3 cites·53 claims
- 3077US2024254185A1Interleukin-2 variants and methods of uses thereofCUGENE INC·Filed 2024·Application pending·0 cites
- 3176US2025326812A1Cytokine-based bioactivatable drugs and methods of uses thereofRUI LINGYUN·Filed 2025·Application pending·0 cites
- 3275US8202976B2Nucleic acid molecules that encode human anti-IFN-gamma neutralizing antibodies as selective IFN-gamma pathway inhibitorsWELCHER ANDREW A·Filed 2010·Granted Jun 19, 2012·2 cites·28 claims
- 3373US9562107B2Carrier immunoglobulinsAMGEN INC·Filed 2014·Granted Feb 7, 2017·1 cites·24 claims
- 3472US11685770B2Stabilized receptor polypeptides and uses thereofAMGEN INC·Filed 2019·Granted Jun 27, 2023·0 cites·6 claims
- 3572US2009048149A1Antagonists of the bradykinin B1 receptorAMGEN INC·Filed 2008·Application pending·0 cites
- 3669US12319722B2Interleukin-15 (IL-15) fusion proteins and uses thereofCUGENE INC·Filed 2019·Granted Jun 3, 2025·0 cites·12 claims
- 3766US2025388641A1Novel interleukin-15 (il-15) fusion proteins and uses thereofCUGENE INC·Filed 2025·Application pending·0 cites
- 3865US8288351B2Antagonists of the bradykinin B1 receptorNG GORDON·Filed 2008·Granted Oct 16, 2012·0 cites·14 claims
- 3965US8278280B2Antagonists of the bradykinin B1 receptorNG GORDON·Filed 2008·Granted Oct 2, 2012·0 cites·14 claims
- 4060US10189912B2Carrier immunoglobulinsAMGEN INC·Filed 2017·Granted Jan 29, 2019·0 cites·24 claims
- 4158US2021269497A1Interleukin-2 variants and methods of uses thereofCUGENE INC·Filed 2019·Application pending·0 cites
- 4252US2022170028A1Novel interleukin-2 variants and bifunctional fusion molecules thereofCUGENE INC·Filed 2020·Application pending·0 cites
- 4352US2023048046A1Novel interleukin-15 (il-15) fusion proteins and uses thereofCUGENE INC·Filed 2020·Application pending·0 cites
- 4452US2023093155A1Cytokine-based bioactivatable drugs and methods of uses thereofCUGENE INC·Filed 2020·Application pending·0 cites
- 4551US2022235109A1Novel interleukin-2 variants for the treatment of cancerCUGENE INC·Filed 2020·Application pending·0 cites
- 4644US2016244497A1Fgf21 mutants and uses thereofAMGEN INC·Filed 2016·Application pending·0 cites
- 4744US2012052069A1Fgf21 mutants and uses thereofBELOUSKI EDWARD JOHN·Filed 2010·Application pending·0 cites
- 4835US6448381B1DNA encoding heparin-binding growth factorBARNES JEWISH HOSPITAL·Filed 1990·Granted Sep 10, 2002·3 cites·2 claims
Join the waitlist — get patent alerts
Get an alert when Yue-Sheng Li files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →